Research programme: chimeric antigen T-cell therapies - bluebird bio

Drug Profile

Research programme: chimeric antigen T-cell therapies - bluebird bio

Alternative Names: CAR T-cell therapy - bluebird bio

Latest Information Update: 19 Apr 2017

Price : $50

At a glance

  • Originator bluebird bio
  • Class CAR-T cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haematological malignancies; Solid tumours

Most Recent Events

  • 01 Apr 2017 Pharmacodynamics data from a preclinical study presented at the 108th Annual Meeting of the American Association for Cancer Research-2017 (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top